Key result
The PRIDE-ACS trial is a planned randomized controlled trial designed to evaluate whether adding 3 months of low-dose rivaroxaban to standard dual antiplatelet therapy reduces major adverse cardiovascular and cerebrovascular events in high-risk patients with acute coronary syndrome.
Why the study?
Residual thrombosis risk contributes to ischaemic events after PCI for ACS, but individualized treatment with low-dose rivaroxaban based on risk stratification remains rare.
Does low-dose rivaroxaban added to DAPT reduce MACCE in high-risk ACS patients after PCI?
RCT (n=3,944)
Open-label
1:1 via Interactive Web Response System
Yes
Does low-dose rivaroxaban added to DAPT reduce MACCE in high-risk ACS patients after PCI?
The PRIDE-ACS trial protocol outlines a study to evaluate whether adding a 3-month course of low-dose rivaroxaban to standard DAPT reduces ischemic events in ACS patients post-PCI identified as high-risk by PARIS score or D-dimer.
Answers are grounded in this paper and cite their sources.
D-dimer/PARIS-guided low-dose rivaroxaban may identify high-risk ACS post-PCI patients; leaves open whether this strategy improves outcomes.
INTRODUCTION: Residual thrombosis risk is an important contributor to ischaemic events in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Although previous studies have shown that rivaroxaban 2.5 mg two times per day in ACS patients with high ischaemic risk can significantly reduce the risk of ischaemic recurrence and mortality, individualised treatment with low-dose rivaroxaban is still rare. Using D-dimer and PARIS (Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients) coronary thrombosis risk score to identify ACS patients at high ischaemic risk, we aim to investigate whether 3-month low-dose rivaroxaban therapy on the basis of dual antiplatelet therapy (DAPT) could result in reduced ischaemic events without increasing bleeding. METHODS AND ANALYSIS: This study is a multicentre, prospective, open-label, randomised controlled trial involving 3944 ACS patients undergoing PCI from more than 40 tertiary hospitals in China (ClinicalTrials.gov NCT05638867). Patients with PARIS coronary thrombosis score ≥3 or D-dimer ≥0.28 µg/mL will be 1:1 randomised to the experimental group (rivaroxaban 2.5 mg two times per day for 3 months on the basis of 1 year standard DAPT) or the control group (1 year standard DAPT only). The primary endpoint of this study is major adverse cardiovascular and cerebrovascular events (MACCE), a composite of death, myocardial infarction, unplanned ischaemia-driven revascularisation and systemic embolic events. The safety endpoint is Bleeding Academic Research Consortium (BARC) type 3 and 5 bleeding events. ETHICS AND DISSEMINATION: Institutional Review Board (IRB) approval by the Ethics Committee of Fuwai Hospital was obtained on 22 April 2023 (Approval No. 2023-1980). The investigators will have access to the final dataset. Trial results will be made public through publication in professional journals. TRIAL REGISTRATION NUMBER: NCT05638867.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2025) conducted an RCT in Acute coronary syndrome after percutaneous coronary intervention (n=3,944). Rivaroxaban vs. Standard dual antiplatelet therapy (DAPT) for 1 year was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, stroke, unplanned ischaemia-driven revascularisation and systemic embolism. The PRIDE-ACS trial is a planned randomized controlled trial designed to evaluate whether adding 3 months of low-dose rivaroxaban to standard dual antiplatelet therapy reduces major adverse cardiovascular and cerebrovascular events in high-risk patients with acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: